<u> </u>		Page 1 of
Ç	omplete if Known	
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	-
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/SY/		BRINKMANN, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001) Transplantation 72, 764-769	
ISYI		MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686	

EXAMINĖR	/Shawquia Young/	<u>-</u>	Date Considered	01/02/2008	
		٠.			

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 1 of

PSUBSLINAS OF FORM 1449/PTO

O 3 1001 E INFORMATION

E DISCLOSURE

STATEMENT BY APPLICANT

	ruge I oj			
Complete if Known				
Application Number	10/578,216			
Filing Date	May 3, 2006			
First Named Inventor	Kevin R. Lynch et al.			
Art Unit	1626·			
Examiner Name	Shawquia Young			
Attorney Docket No.	198P000944USWO			

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.	Number-Kind Code	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear	t
		FORE	EIGN PATEN	T DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	7
Initials	No.		MINT-DD-1111	Applicant of Cited Document	Relevant Passages Or Relevant Figures Appear	
Initials	No.	Country Code/Number/Kind Code	 	Applicant of Cited Document		
Initials /SY/	No.	•	07-13-2005	Ikemoto et al.		

EXAMINER	Date Considered
/Shawquia Young/	01/02/2008

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	rage 1	OJ O
.C	omplete if Known	
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ISYI		US-6,875,757 B2	04-05-2005	Miller et al.	
/SY/		US-7,060,697 B2	06-13-2006	Marsilje et al.	
/SY/		US-7,064,217 B2	06-20-2006	Macdonald et al.	
/SY/		US-7,241,790 B2	07-10-2007	Lynch et al.	
/SY/		US-2004/0224941 A1	11-11-2004	Seko et al.	
/SY/		US-2005/0032744 A1	02-10-2005	Michaelis et al.	
/SY/		US-2005/0023386 A1	02-24-2005	Nishi et al.	
/SY/		US-2005/0107447 A1	05-19-2005	Lynch et al.	
/SY/		US-2006/0135786 A1	06-22-2006	Saha et al.	
/SY/		US-2006/0223866 A1	10-05-2006	Evindar et al.	
/SY/		US-2007/0088002 A1	04-19-2007	Lynch et al.	
/SY/		US-2007-0191313 A1	08-16-2007	Beard et al.	<u> </u>

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code/Number/Kind Code				
ISYI		GB 950,388	02-26-1964	Smith Kline & French Laboratories		
ISYI		JP 2002-316985	10-31-2002	Takehide et al.	English Abstract provided	
ISYI		WO 99/35259	07-15-1999	Munroe et al.	·	
/SY/		WO 01/60819 A1	08-23-2001	Ueno et al.		
/SY/		WO 02/064616 A2	08-22-2002	Macdonald et al.		
'/SY/		WO 05/032465 A2	04-14-2005	Doherty et al.		

EXAMINER /Shawquia Young/	Date Considered 01/02/2008
	

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	1480 2 0)
C	omplete if Known
Application Number	10/578,216
Filing Date	May 3, 2006
First Named Inventor	Kevin R. Lynch et al.
Art Unit	1626
Examiner Name	Shawquia Young
Attorney Docket No.	198P000944USWO

/SY/	WO 2006/088944 A1		Lynch et al. Albert et al.	<u> </u>	\dashv
ISYI I	WO 2007/085451 A2 WO 2007/086001 A2		Bolli et al.		+
ISYI	WO 2007/091396 A1	<u> </u>	Hasegawa et al.	٠.	\top

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	e No. Include name of the author (in CAPITAL, LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
ISYI		International Search Report for PCT/US2004/036563	
ISYI		BANDINI, Marco et al., "An Effective and Useful Synthesis of Enantiomerically Enriched Arylglycinols", Eur. J. Chem. 2001, 1937-1942	
ISYI		BEILSTEIN, XP-002380276	Щ
/SY/		BERTUS, Phillipe et al., "New and easy route to primary cyclopropylamines from nitriles", <i>Chem Commun</i> , 2001, 1792-1793	
/SY/		BRINKMANN, V. et al., V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002) <i>J Biol Chem</i> 277, 21453-21457	
ISYI		BRINKMANN, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001) Transplantation 72, 764-769	·
ISYI		BURGER, Alfred et al., "1-Methyl-2-phenylcyclopropylamine", Journal of Medicine and Pharmaceutical Chemistry, Vol. 4, No. 3, 1961	
'/SY/		CHIBA, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., and Hoshino, Y. (1998) <i>J Immunol</i> 160, 5037-5044	·
/SY/		CLAIR, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003)	

EXAMINER-	/Shawquia Young/	Date Considered 01/02/2008

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		rage 5 0j 0
Co	omplete if Known	
Application Number	10/578,216	•
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

	Cancer Res 63, 5446-5453	\Box
/SY/	CLEMENS, J. J., Davis, M. D., Lynch, K. R., and Macdonald, T. L. (2003) Bioorg Med Chem Lett 13, 3401-3404	
ISYI	CLEMENS, Jeremy et al., "Synthesis of 4(5)-phenylimidazole-based analogs of sphingosine-1-phosphate and FTY720: Discovery of potent S1P ₁ receptor agonists", <i>Bioorganic & Medicinal Chemistry Letters</i> 15 (2005) 3568-3572	
/SY/	CROSIGNANI, Stefano et al., "4-Naphthyl-Substituted Bis(Oxazoline): a New Easily Recoverable and Efficient Chiral Ligand in Asymetric Catalysis of the Diels-Alder Reaction", <i>Tetrahedron</i> 54 (1998) 15721-15730	
ISYI	DAVIS, Michael D. et al., "Sphingosine 1-Phosphate Analogs as Receptor Antagonists", <i>The Journal of Biological Chemistry</i> , Vol. 280, No. 11, 2005, 9833-9841	
ISYI	FORREST, M., Sun, S. Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., Mills, S., Nomura, N., Rosen, H., Rosenbach, M., Shei, G. J., Singer, II, Tian, M., West, S., White, V., Xie, J., Proia, R. L., and Mandala, S. (2004) <i>J Pharmacol Exp Ther</i> 309, 758-768	
ISYI	FOSS, Frank W. et al., "Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists", <i>Bioorganic & Medicinal Chemistry</i> 15, 2007, 663-677	
ISYI	FUJINO, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., and Li, X. K. (2003) <i>J Pharmacol Exp Ther</i> 305 , 70-77	
ISYI	GRALER, M. H., and Goetzl, E. J. (2004) FASEB 18, 551-553	
ISYI	HALE, Jeffrey J. et al., "Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720", Bioorganic & Medicinal Chemistry Letters 14, 2004, 3351-3355	
TSYI	HALE, J. J., Doherty, G., Toth, L., Mills, S. G., Hajdu, R., Ann Keohane,	

EXAMINER	/Shawquia Young/	Date Considered 01/02/2008	
	·		

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 uge 4			
Complete if Known			
Application Number	10/578,216		
Filing Date	May 3, 2006		
First Named Inventor	Kevin R. Lynch et al.		
Art Unit	1626		
Examiner Name	Shawquia Young		
Attorney Docket No.	198P000944USWO		

ISYI	C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Forrest, M., Sun, S. Y., West, S., Xie, H., Nomura, N., Rosen, H., and Mandala, S. (2004) <i>Bioorg Med Chem Lett</i> 14, 3501-3505	
ISYI	HALE, J. J., Doherty, G., Toth, L., Li, Z., Mills, S. G., Hajdu, R., Ann Keohane, C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Rosen, H., and Mandala, S. (2004) <i>Bioorg Med Chem Lett</i> 14, 3495-3499	
<i>I</i> SY <i>I</i>	HALE, Jeffrey J. et al., "A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phophate-1 Receptor Agonists", <i>J Med Chem</i> , 2004, 47, 6662-6665	
/SY/	HANESSIAN, Stephen et al., "Constrained azacyclic analogues of the immunomodulatory agent FTY270 as molecular probes for sphingosine 1-phosphate receptors:, <i>Bioorganic & Medicinal Chemistry Letters</i> 17, 2007, 491-494	
ISYI	HOSHINO, Y., Yanagawa, Y., Ohtsuki, M., Nakayama, S., Hashimoto, T., and Chiba, K. (1999) Transplant Proc 31, 1224-1226	
/SY/	IM, D. S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G. J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., George, S. R., and Lynch, K. R. (2000) <i>J Biol Chem</i> 275, 14281-14286	
ISYI	JONES, L., Schumm, J. S., and Tour, J. M. (1997) J Org Chem 62, 1388- 1410	
ISYI	KAISER, Carl et al., "2-Substituted Cyclopropylamines. I. Derivatives and Analogs of 2-Phenylcyclopropylamine", XP009032189, November 1962, 1243-1265	
ISYI	KAWASAKI, Ken-ichi et al., "Enantioselective Allylic Oxidation of Cycloalkenes by Using Cu(II)-Tris(oxazoline) Complex as a Catalyst", <i>Tetrahedron</i> , Vol. 53, No. 18, 1997, 6337-6350	-
ISYI	KHAREL, Yugesh et al., "Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY 720", <i>J Bio Chem</i> , Vol. 280, No. 44, November 4, 2005, 36865-36872	

EXAMINER	/Shawquia Young/	Date Considered	01/02/2008

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Tage 3 of		
Complete if Known		
10/578,216		
May 3, 2006 .		
Kevin R. Lynch et al.		
1626		
Shawquia Young		
198P000944USWO		

/SY/	KIMURA, T., Sato, K., Malchinkhuu, E., Tomura, H., Tamama, K., Kuwabara, A., Murakami, M., and Okajima, F. (2003) <i>Arterioscler Thromb Vasc Biol</i> 23, 1283-1288	
ISYI	KIUCHI, M., Adachi, K., Kohara, T., Minoguchi, M., Hanano, T., Aoki, Y., Mishina, T., Arita, M., Nakao, N., Ohtsuki, M., Hoshino, Y., Teshima, K., Chiba, K., Sasaki, S., and Fujita, T. (2000) J Med Chem 43, 2946-2961	
ISYI	KON, J., Sato, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) <i>J Biol Chem</i> 274, 23940-23947	
ISYI	LEE, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555	
ISYI	LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337	
/SY/	LI, Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", <i>Journal of Medicinal Chemistry</i> , Vol. 48, No. 20, October 6, 2005, 6169-6173	
/SY/	MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686	
<i>I</i> SY/	MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349.	
/SY/	MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360	
/SY/	SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) <i>J Biol Chem</i> 278, 47281-47290	
ISYI	SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P ₁ antagonist in vivo", Nature Chemical Biology, Vol. 2, August 2006, 434-441	
/SY/	SANNA, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M. Y., Peterson, M. S.,	-

EXAMINER /Shawquia Young/	Date Considered 01/02/2008

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	1 age o oj o	
Complete if Known		
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

ISYI	Webb, B., Lefebvre, S., Chun, J., Gray, N., and Rosen, H. (2004) <i>J Biol Chem</i> 279, 13839-13848	. (
ISYI	SUZUKI, S., Enosawa, S., Kakefuda, T., Li, X. K., Mitsusada, M., Takahara, S., and Amemiya, H. (1996) Transpl Immunol 4, 252-255	
ISYI	VAN BROCKLYN, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., and Spiegel, S. (1999) <i>J Biol Chem</i> 274 , 4626-4632	
/SY/	VOGLER, Rüdiger et al., "Sphingosine-1-Phosphate and Its Paradoxical Effects on Critical Parameters of Cutaneous Wound Healing", <i>The Journal of Investigative Dermatology</i> , Vol. 48, No. 20, 2005, 6169-6173	·
/SY/	XIE, J. H., Nomura, N., Koprak, S. L., Quackenbush, E. J., Forrest, M. J., and Rosen, H. (2003) <i>J Immunol</i> 170, 3662-3670	
ISYI	YANAGAWA, Y., Hoshino, Y., and Chiba, K. (2000) Int J Immunopharmacol 22, 597-602	
ISYI	YANAGAWA, Y., Hoshino, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., Sugahara, K., and Chiba, K. (1999) <i>Transplant Proc</i> 31, 1227-1229	
ISYI	YANG, Z., Chen, M., Fialkow, L. B., Ellett, J. D., Wu, R., Brinkmann, V., Nadler, J. L., and Lynch, K. R. (2003) Clin Immunol 107, 30-35	
ISYI	ZHANG, T., Nanney, L. B., Luongo, C., Lamps, L., Heppner, K. J., DuBois, R. N., and Beauchamp, R. D. (1997) Cancer Res 57, 169-175	
<i>I</i> SY/	ZHANG, Y. H. et al., "Sphingosine-1-Phosphate Via Activation of a G-Protein-Coupled Receptor(s) Enhances the Excitability of Rat Sensory Neurons", J Neurophysiol 96, 2006, 1042-1052	
ISYI	ZHANG, Y. H. et al., "Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons", <i>J Physiol</i> 575.1, 2006, 101-113	•

EXAMINER	/Shawquia Young/	 Date Considered	01/02/2008
,	-		•

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. OCT 0 6 200 Ader. Complete if Known

ute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/578,216 Filing Date 05/03/06 First Named Inventor Kevin R. Lynch Art Unit Unknown **Examiner Name** <u>Unknown</u> Attorney Docket Number 00944-03

(Use as many sheets as necessary)

US-

Sheet of

			U. S. PATENT		Daniel Columns Lines Mines
Examiner nitials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SY/	1	^{US-} 6,069,251	05/30/2000	Thurkauf, et al.	Entire Document
SY/ SY/	2	^{US-} 5,405,988	04/11/1995	Klar, et al.	Entire Document
511	3	^{US-} 4,939,130	07/03/1990	Jaeggi, et al.	Entire Document
		US-			
		US-			
		US-		,	
		US-			
		UŞ-			
		US-			
		US-			
	1	US-		0	
-		US-			
		U\$-			
	1	US-	 		

-	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. ¹		Patent Document Ide ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	,Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7°			
/SY/	4	wo	2004/010987	A2	07/23/2003	Brinkmann, et al.	Entire Document				
/SY/	5	wo	02/076995	A2	10/03/2002	Albert, et al.	Entire Document				
ISYI	6	wo	2004/103306	A2	12/02/2004	Pan, et al.	Entire Document				
ISYI	7	wo	2004/096752	A 1	11/11/2004	Hinterding, et al.	Entire Document				
/SY/	8	wo	2004/028521	A2	04/08/2004	Foster, et al.	Entire Document	П			

Examiner Signature	/Shawquia Young/	Date Considered	01/02/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For the standard ST.3). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

00944-03

Under the Paperwork Reduction Act of 1995, no persons are required to n		emplete if Known
Substitute for form 1449A/PTO		implete il Kilowii
	Application Number	10/578.216
INFORMATION DISCLOSURE	Filing Date	05/03/06
STATEMENT BY APPLICANT	First Named Inventor	Kevin R. Lynch
STATEMENT DI ALL ELOAM	Art Unit	Unknown
(Use as many sheets as necessary)	Examiner Name	Unknown

3

of

ับร-

Attorney Docket Number

Sheet U. S. PATENT DOCUMENTS Pages, Columns, Lines, Where Cite **Publication Date** Name of Patentee or **Document Number** Examiner Relevant Passages or Relevant MM-DD-YYYY Applicant of Cited Document mitlals* No. Figures Appear Number-Kind Code² (if known) IIS. US-US-US-US-US-US-IIS. US-US-US-US-US-US-US-US-

- ·	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.		atent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
/SY/	9	wo	2004/024673	Al	03/25/2004	Buehlmayer, et al.	Entire Document				
/SY/	10	wo	2004/017917	A2	03/04/2004	Evans, et al.	Entire Document				
/SY/	11	wo	2004/103279	A2	12/02/2004	Colandrea, et al.	Entire Document				
/SY/	12	wo	03/061567	A2	07/31/2003	Doherty, et al.	Entire Document				
ISYI	13	wo	03/059880	Äl	07/24/2003	Sankyo Company, Ltd.	Entire Document	l			

Examiner Signature	/Shawquia Young/	Date Considered	01/02/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For the page of the indication of the page of the Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. S Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. S Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

· Subs	titute for form 1449A/PTO			Complete if Known		
0000	114(0 (SF 107))) 1 1 4 4 0 0 1 1 0			Application Number	10/578.216	
IN	FORMATION DI	SCLOS	URE	Filing Date	05/03/06	
	TATEMENT BY			First Named Inventor	Kevin R. Lynch	
	IAIEMENI Di /	AI I LIO		Art Unit	Unknown	
	(Use as many sheets as	necessary)		Examiner Name	Unknown	
Sheet	:3	of	:3_	Attorney Docket Number	00944-03	

<u> </u>			U. S. PATENT		
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
mitials*	No.	Number-Kind Code ^{2 (II known)}	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
-		US-			
	t —	US-			
		US-			
	\top	US-			
	1	US-			
	1	US-			
	1	US-			

	FOREIGN PATENT DOCUMENTS									
Examiner initials*	Cite No.1		ent Document Number ⁴ Kind Code ³ (<i>if known</i>)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶		
/SY/	14	wo	02/092068	A1	11/21/2002	Ono Pharmaceutical	Entire Document			
								<u> </u>		
						·		 		
								-		

Examiner	101 V 1	Date 01/02/2008	
	/Shawquia Young/	Considered 01/02/2000	
Signature	Totaliquia Tourigi	Considered	
1			

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.\(^1\) Applicant's unique citation designation number (optional).\(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.\(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).\(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.\(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.